A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

NCT01959529 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

7637

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: insulin degludec
DRUG: insulin glargine

Sponsor

Novo Nordisk A/S